Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

Equality Impact Assessment (Guidance development) (PDF 156 KB)

Final draft guidance

Final appraisal document (PDF 242 KB)

Committee papers - FAD (PDF 3.6 MB)

Draft guidance

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) (PDF 301 KB)

Committee papers - ACM1 (PDF 5.96 MB)

Final scope (PDF 214 KB)

Final appraisal document - TA528 (PDF 417 KB)

Final appraisal document - TA528 (MAA) (PDF 540 KB)

Committee papers - TA528 (ACM2) (PDF 3.53 MB)

Public committee slides - TA528 (ACM2) (PDF 646 KB)

Appraisal consultation document (PDF version) - TA528 (PDF 426 KB)

Committee papers - TA528 (ACM1) (PDF 12.45 MB)

Public committee slides - TA528 (clinical) (PDF 761 KB)

Final stakeholder list - TA528 (PDF 259 KB)

Equality impact assessment (Scoping) - TA528 (PDF 176 KB)